You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 4, April 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (151)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Trimethoprim-Sulfamethoxazole Therapy for Nocardia Infections

Raymond A. Smego, Jr, MD; Mark B. Moeller, MD; Harry A. Gallis, MD

Arch Intern Med. 1983;143(4):711-718.


Abstract

• The optimal therapy for infections due to Nocardia species has not been established. To assess the efficacy of trimethoprim-sulfamethoxazole (TMP-SMX), we reviewed the records of 19 patients with Nocardia infections seen at Duke University Medical Center, Durham, NC, who were treated with this drug, either alone or in combination with other antibiotics or a surgical procedure. Underlying diseases or therapy causing immunosuppression were present in all but five cases. Sites of involvement were lung (ten of 19), wound (two of 19), and brain (two of 19); five of 19 patients had disseminated disease. The mean duration of therapy was 7.2 months. Overall cure or improvement was achieved in 89% (17/19) of cases; 80% of patients with disseminated disease and 60% of those with CNS involvement recovered. This experience, and accumulated clinical evidence in the literature, indicates that TMP-SMX should be considered the therapeutic drug of choice in infections due to Nocardia species.

(Arch Intern Med 1983;143:711-718)



Author Affiliations

From the Division of Infectious Diseases, the Department of Medicine, Duke University Medical Center, Durham, NC.


Footnotes

Accepted for publication Oct 18, 1982.

Reprint requests to Box 3306, Duke University Medical Center, Durham, NC 27710 (Dr Smego).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Into the Woods
Safdar et al.
NEJM 2007;356:943-947.
FULL TEXT  

Endogenous Nocardia asteroides Endophthalmitis
Ng et al.
Arch Ophthalmol 2002;120:210-213.
FULL TEXT  

Chronic non-healing ulcers of the scalp after trauma
Postgrad. Med. J. 2000;76:439i-439.
FULL TEXT  

Biochemical-Genetic Analysis and Distribution of FAR-1, a Class A beta -Lactamase from Nocardia farcinica
Laurent et al.
Antimicrob. Agents Chemother. 1999;43:1644-1650.
ABSTRACT | FULL TEXT  

A Palmar Chancre and Multiple Proximal Erythematous Nodules
Johnson and Meier
Arch Dermatol 1996;132:967-968.
ABSTRACT  

Primary Cutaneous Nocardiosis Mimicking Sporotrichosis
Wlodaver et al.
Arch Dermatol 1988;124:659-660.
ABSTRACT  

Primary Lymphocutaneous Nocardia brasiliensis Infection
Moeller and Burton
Arch Dermatol 1986;122:1180-1182.
ABSTRACT  

Disseminated Nocardia brasiliensis Infection Following Cryptococcal Disease
Schreiner et al.
Arch Dermatol 1986;122:1186-1190.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.